Health Care & Life Sciences » Biotechnology | Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
SG&A Expense
1,989.70
3,177.50
2,418.00
3,803.90
9,022.50
13,491.60
EBIT
1,989.70
3,177.50
2,418.00
3,803.90
9,022.50
13,491.60
Unusual Expense
3,891.80
777.50
1,582.60
63.60
173.90
216.50
Non Operating Income/Expense
3.10
3.30
11.50
34.50
10.40
7.80
Pretax Income
1,901.10
2,403.30
843.10
3,695.20
9,145.80
12,816.30
Consolidated Net Income
1,901.10
2,403.30
843.10
3,695.20
9,145.80
12,816.30
Net Income
1,901.10
2,403.30
843.10
3,695.20
9,145.80
12,816.30
Net Income After Extraordinaries
1,901.10
2,403.30
843.10
3,695.20
9,145.80
12,816.30
Net Income Available to Common
1,901.10
2,403.30
843.10
3,695.20
9,145.80
12,816.30
EPS (Basic)
0.19
0.24
0.08
0.29
0.61
0.68
Basic Shares Outstanding
9,719.30
9,871.00
10,827.00
12,765.00
15,014.00
18,942
EPS (Diluted)
0.18
0.24
0.08
0.29
0.61
0.68
Diluted Shares Outstanding
10,571.30
9,871.00
10,827.00
12,765.00
15,014.00
18,942
EBITDA
1,989.70
3,177.50
2,418.00
3,803.90
9,022.50
-
Non-Operating Interest Income
2.10
-
3.80
10.60
61.00
451.10

About Fennec Pharmaceuticals

View Profile
Address
Research Triangle Park
Durham North Carolina 27709
United States
Employees -
Website http://www.fennecpharma.com
Updated 07/08/2019
Fennec Pharmaceuticals, Inc. is a small stage biotechnology company, which engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.